{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:13:09Z","timestamp":1793333589733,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92297-x","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T10:10:26Z","timestamp":1741428626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Shenchao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjia","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"92297_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur. Urol. 84, 176\u2013190. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.029 (2023).","journal-title":"Eur. Urol."},{"key":"92297_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers 9, 58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"92297_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ju.0000000000000593","volume":"203","author":"CR Ritch","year":"2020","unstructured":"Ritch, C. R. et al. Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J. Urol. 203, 505\u2013511. https:\/\/doi.org\/10.1097\/ju.0000000000000593 (2020).","journal-title":"J. Urol."},{"key":"92297_CR4","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ucl.2020.10.005","volume":"47","author":"SS Nair","year":"2020","unstructured":"Nair, S. S., Weil, R., Dovey, Z., Davis, A. & Tewari, A. K. The tumor microenvironment and immunotherapy in prostate and bladder cancer. Urol. Clin. North Am. 47, e17\u2013e54. https:\/\/doi.org\/10.1016\/j.ucl.2020.10.005 (2020).","journal-title":"Urol. Clin. North Am."},{"key":"92297_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","volume":"112","author":"NM Gandhi","year":"2013","unstructured":"Gandhi, N. M., Morales, A. & Lamm, D. L. Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer. BJU Int. 112, 288\u2013297. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11754.x (2013).","journal-title":"BJU Int."},{"key":"92297_CR6","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han, J., Gu, X., Li, Y. & Wu, Q. Mechanisms of BCG in the treatment of bladder cancer-current Understanding and the prospect. Biomed. Pharmacother. 129, 110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393 (2020).","journal-title":"Biomed. Pharmacother"},{"key":"92297_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","volume":"69","author":"PL Crispen","year":"2020","unstructured":"Crispen, P. L. & Kusmartsev, S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol. Immunother. 69, 3\u201314. https:\/\/doi.org\/10.1007\/s00262-019-02443-4 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"92297_CR8","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","volume":"51","author":"DF Ward Grados","year":"2022","unstructured":"Ward Grados, D. F., Ahmadi, H., Griffith, T. S. & Warlick, C. A. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol. Investig. 51, 2226\u20132251. https:\/\/doi.org\/10.1080\/08820139.2022.2118606 (2022).","journal-title":"Immunol. Investig"},{"key":"92297_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625. https:\/\/doi.org\/10.1038\/s41585-018-0055-4 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"92297_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/tcrm.S158753","volume":"14","author":"D Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A. & Grivas, P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther. Clin. Risk Manag. 14, 1019\u20131040. https:\/\/doi.org\/10.2147\/tcrm.S158753 (2018).","journal-title":"Ther. Clin. Risk Manag"},{"key":"92297_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Actin cytoskeleton vulnerability to disulfide stress mediates Disulfidptosis. Nat. Cell. Biol. 25, 404\u2013414. https:\/\/doi.org\/10.1038\/s41556-023-01091-2 (2023).","journal-title":"Nat. Cell. Biol."},{"key":"92297_CR12","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.18632\/aging.204782","volume":"15","author":"C Qi","year":"2023","unstructured":"Qi, C., Ma, J., Sun, J., Wu, X. & Ding, J. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma. Aging (Albany NY). 15, 5075\u20135095. https:\/\/doi.org\/10.18632\/aging.204782 (2023).","journal-title":"Aging (Albany NY)"},{"key":"92297_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12876-023-03020-x","volume":"23","author":"P Chen","year":"2023","unstructured":"Chen, P., Yu, J., Luo, Q., Li, J. & Wang, W. Construction of disulfidptosis-related LncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma. BMC Gastroenterol. 23, 382. https:\/\/doi.org\/10.1186\/s12876-023-03020-x (2023).","journal-title":"BMC Gastroenterol."},{"key":"92297_CR14","doi-asserted-by":"publisher","first-page":"20230825","DOI":"10.1515\/med-2023-0825","volume":"18","author":"XM Li","year":"2023","unstructured":"Li, X. M. et al. Identification of disulfidptosis-related genes and immune infiltration in lower-grade glioma. Open. Med. (Wars) 18, 20230825. https:\/\/doi.org\/10.1515\/med-2023-0825 (2023).","journal-title":"Open. Med. (Wars)"},{"key":"92297_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10020-023-00739-x","volume":"29","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning. Mol. Med. 29, 145. https:\/\/doi.org\/10.1186\/s10020-023-00739-x (2023).","journal-title":"Mol. Med."},{"key":"92297_CR16","doi-asserted-by":"publisher","first-page":"1198826","DOI":"10.3389\/fimmu.2023.1198826","volume":"14","author":"J Liang","year":"2023","unstructured":"Liang, J. et al. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Front. Immunol. 14, 1198826. https:\/\/doi.org\/10.3389\/fimmu.2023.1198826 (2023).","journal-title":"Front. Immunol."},{"key":"92297_CR17","doi-asserted-by":"publisher","first-page":"102001","DOI":"10.1016\/j.tranon.2024.102001","volume":"46","author":"Z Gui","year":"2024","unstructured":"Gui, Z. et al. Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in cervical cancer. Transl. Oncol. 46, 102001. https:\/\/doi.org\/10.1016\/j.tranon.2024.102001 (2024).","journal-title":"Transl. Oncol."},{"key":"92297_CR18","doi-asserted-by":"publisher","first-page":"21565","DOI":"10.1038\/s41598-023-48653-w","volume":"13","author":"Y Ye","year":"2023","unstructured":"Ye, Y. et al. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer. Sci. Rep. 13, 21565. https:\/\/doi.org\/10.1038\/s41598-023-48653-w (2023).","journal-title":"Sci. Rep."},{"key":"92297_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/bs9.0000000000000149","volume":"5","author":"YJ Zhou","year":"2023","unstructured":"Zhou, Y. J. et al. PD-L1: expression regulation. Blood Sci. 5, 77\u201391. https:\/\/doi.org\/10.1097\/bs9.0000000000000149 (2023).","journal-title":"Blood Sci."},{"key":"92297_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012 (2022).","journal-title":"Ann. Oncol."},{"key":"92297_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/s1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931\u2013945. https:\/\/doi.org\/10.1016\/s1470-2045(21)00152-2 (2021).","journal-title":"Lancet Oncol."},{"key":"92297_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/s1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Durvalumab alone and durvalumab plus Tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21, 1574\u20131588. https:\/\/doi.org\/10.1016\/s1470-2045(20)30541-6 (2020).","journal-title":"Lancet Oncol."},{"key":"92297_CR23","doi-asserted-by":"publisher","first-page":"1180404","DOI":"10.3389\/fendo.2023.1180404","volume":"14","author":"S Zhao","year":"2023","unstructured":"Zhao, S. et al. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. Front. Endocrinol. (Lausanne) 14, 1180404. https:\/\/doi.org\/10.3389\/fendo.2023.1180404 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"92297_CR24","doi-asserted-by":"publisher","first-page":"1198878","DOI":"10.3389\/fimmu.2023.1198878","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen, H., Yang, W., Li, Y., Ma, L. & Ji, Z. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. Front. Immunol. 14, 1198878. https:\/\/doi.org\/10.3389\/fimmu.2023.1198878 (2023).","journal-title":"Front. Immunol."},{"key":"92297_CR25","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui, R., Zhou, L. & He, S. Cancer immunotherapies: advances and bottlenecks. Front. Immunol. 14, 1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476 (2023).","journal-title":"Front. Immunol."},{"key":"92297_CR26","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea, L. P., Mendez-Marti, S., Kim, D. & Aragon-Ching, J. B. Role of immunotherapy in bladder cancer. Cancer Treat. Res. Commun. 26, 100296. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"92297_CR27","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. & van der Heijden, M. S. The bladder cancer immune micro-environment in the context of response to immune checkpoint Inhibition. Front. Immunol. 14, 1235884. https:\/\/doi.org\/10.3389\/fimmu.2023.1235884 (2023).","journal-title":"Front. Immunol."},{"key":"92297_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13062-024-00588-6","volume":"19","author":"L Bao","year":"2024","unstructured":"Bao, L. et al. Comprehensive pan-cancer analysis indicates UCHL5 as a novel cancer biomarker and promotes cervical cancer progression through the Wnt signaling pathway. Biol. Direct. 19, 139. https:\/\/doi.org\/10.1186\/s13062-024-00588-6 (2024).","journal-title":"Biol. Direct"},{"key":"92297_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2967\/jnumed.115.167932","volume":"57","author":"B Behnam Azad","year":"2016","unstructured":"Behnam Azad, B. et al. Targeted imaging of the atypical chemokine receptor 3 (ACKR3\/CXCR7) in human cancer xenografts. J. Nucl. Med. 57, 981\u2013988. https:\/\/doi.org\/10.2967\/jnumed.115.167932 (2016).","journal-title":"J. Nucl. Med."},{"key":"92297_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41420-022-00956-z","volume":"8","author":"HJ Yang","year":"2022","unstructured":"Yang, H. J., Liu, T. & Xiong, Y. Anti-cancer effect of LINC00478 in bladder cancer correlates with KDM1A-dependent MMP9 demethylation. Cell. Death Discov. 8, 242. https:\/\/doi.org\/10.1038\/s41420-022-00956-z (2022).","journal-title":"Cell. Death Discov."},{"key":"92297_CR31","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3892\/ol.2017.7510","volume":"15","author":"B Jiang","year":"2018","unstructured":"Jiang, B. et al. Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9. Oncol. Lett. 15, 1573\u20131579. https:\/\/doi.org\/10.3892\/ol.2017.7510 (2018).","journal-title":"Oncol. Lett."},{"key":"92297_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3881\/j.issn.1000-503X.2011.04.009","volume":"33","author":"J Wen","year":"2011","unstructured":"Wen, J., Li, H. Z., Ji, Z. G., Yan, W. G. & Shi, B. B. Expressions of receptor tyrosine kinases mRNA and protein in carcinoma of bladder. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 33, 393\u2013396. https:\/\/doi.org\/10.3881\/j.issn.1000-503X.2011.04.009 (2011).","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"92297_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.18632\/aging.103787","volume":"13","author":"K Jin","year":"2021","unstructured":"Jin, K. et al. Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database. Aging (Albany NY) 13, 1859\u20131871. https:\/\/doi.org\/10.18632\/aging.103787 (2021).","journal-title":"Aging (Albany NY)"},{"key":"92297_CR34","doi-asserted-by":"publisher","first-page":"553399","DOI":"10.3389\/fonc.2020.553399","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. CD8+ T cell co-expressed genes correlate with clinical phenotype and microenvironments of urothelial cancer. Front. Oncol. 10, 553399. https:\/\/doi.org\/10.3389\/fonc.2020.553399 (2020).","journal-title":"Front. Oncol."},{"key":"92297_CR35","doi-asserted-by":"publisher","first-page":"936305","DOI":"10.3389\/fgene.2022.936305","volume":"13","author":"X Mo","year":"2022","unstructured":"Mo, X. et al. A novel pyroptosis-related prognostic LncRNAs signature, tumor immune microenvironment and the associated regulation axes in bladder cancer. Front. Genet. 13, 936305. https:\/\/doi.org\/10.3389\/fgene.2022.936305 (2022).","journal-title":"Front. Genet."},{"key":"92297_CR36","doi-asserted-by":"publisher","unstructured":"Tong, H. et al. An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer. Biosci. Rep. 41. https:\/\/doi.org\/10.1042\/bsr20203944 (2021).","DOI":"10.1042\/bsr20203944"},{"key":"92297_CR37","doi-asserted-by":"publisher","unstructured":"Shen, C. et al. The analysis of PTPN6 for bladder cancer: an exploratory study based on TCGA. Dis. Markers. 2020,  4312629. https:\/\/doi.org\/10.1155\/2020\/4312629 (2020).","DOI":"10.1155\/2020\/4312629"},{"key":"92297_CR38","doi-asserted-by":"publisher","first-page":"29730","DOI":"10.1074\/jbc.M202435200","volume":"277","author":"H Park","year":"2002","unstructured":"Park, H., Kim, Y., Lim, Y., Han, I. & Oh, E. S. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J. Biol. Chem. 277, 29730\u201329736. https:\/\/doi.org\/10.1074\/jbc.M202435200 (2002).","journal-title":"J. Biol. Chem."},{"key":"92297_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.urolonc.2009.03.018","volume":"28","author":"HR Contreras","year":"2010","unstructured":"Contreras, H. R. et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol. Oncol. 28, 534\u2013540. https:\/\/doi.org\/10.1016\/j.urolonc.2009.03.018 (2010).","journal-title":"Urol. Oncol."},{"key":"92297_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12943-018-0908-8","volume":"17","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p\/G3BP2\/SRC\/FAK axis. Mol. Cancer 17, 161. https:\/\/doi.org\/10.1186\/s12943-018-0908-8 (2018).","journal-title":"Mol. Cancer"},{"key":"92297_CR41","doi-asserted-by":"publisher","first-page":"154431","DOI":"10.1016\/j.prp.2023.154431","volume":"245","author":"T Liang","year":"2023","unstructured":"Liang, T. et al. Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer. Pathol. Res. Pract. 245, 154431. https:\/\/doi.org\/10.1016\/j.prp.2023.154431 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"92297_CR42","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753 (2021).","journal-title":"Pharmacol. Ther."},{"key":"92297_CR43","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921\u2013925. https:\/\/doi.org\/10.1126\/science.1252510 (2014).","journal-title":"Science"},{"key":"92297_CR44","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.celrep.2015.08.033","volume":"12","author":"F Kratochvill","year":"2015","unstructured":"Kratochvill, F. et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell. Rep. 12, 1902\u20131914. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.033 (2015).","journal-title":"Cell. Rep."},{"key":"92297_CR45","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596 (2015).","journal-title":"N. Engl. J. Med."},{"key":"92297_CR46","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655\u20131657. https:\/\/doi.org\/10.1126\/science.296.5573.1655 (2002).","journal-title":"Science"},{"key":"92297_CR47","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/mmr.2018.9713","volume":"19","author":"Y Xie","year":"2019","unstructured":"Xie, Y. et al. PI3K\/Akt signaling transduction pathway, erythropoiesis and Glycolysis in hypoxia (Review). Mol. Med. Rep. 19, 783\u2013791. https:\/\/doi.org\/10.3892\/mmr.2018.9713 (2019).","journal-title":"Mol. Med. Rep."},{"key":"92297_CR48","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1158\/0008-5472.Can-06-1182","volume":"66","author":"E L\u00f3pez-Knowles","year":"2006","unstructured":"L\u00f3pez-Knowles, E. et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66, 7401\u20137404. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1182 (2006).","journal-title":"Cancer Res."},{"key":"92297_CR49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4161\/cbt.21793","volume":"13","author":"RJ Dickstein","year":"2012","unstructured":"Dickstein, R. J. et al. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol. Ther. 13, 1325\u20131338. https:\/\/doi.org\/10.4161\/cbt.21793 (2012).","journal-title":"Cancer Biol. Ther."},{"key":"92297_CR50","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92297-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T10:10:31Z","timestamp":1741428631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92297"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92297-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Wenzhou Central Hospital and was performed in accordance with the Declaration of Helsinki. Animal protocols including euthanasia methods were approved by the Institutional Animal Care and Use Committee of Wenzhou Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8130"}}